Kadimastem expands stem cell-based collaboration with Merck Serono

11/4/2013 | Reuters

Kadimastem, an Israel-based regenerative medicine company, agreed to expand a stem cell-based drug screening collaboration with Merck Serono that started in 2012. The partnership focuses on developing compounds to differentiate stem cells into oligodendrocytes, or brain cells that produce myelin, which are destroyed by the immune system in multiple sclerosis.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ